Results 91 to 100 of about 71,664 (187)
, 2011 Trastuzumab is standard of care in the treatment of human epidermal growth factor receptor (HER)-2+ early and advanced breast cancer. Recently, it has been approved for the treatment of HER-2+ advanced gastric cancer.
Jan H.M. Schellens +2 more
core +1 more source
Advances in Spatial Heterogeneity and Cellular Localization Specificity of Intratumoral Bacteria
Cancer Science, EarlyView.Spatial localization of intratumoral bacteria governs their functional roles in tumor progression, metastasis, and treatment responses, with guiding significance for clinical management, as reviewed across three spatial paradigms. ABSTRACT Bacteria in tumors are increasingly recognized to be a part of the tumor microenvironment and their biological ...
Minlan Ren +11 more
wiley +1 more source
Development of the G3 Designed ankyrin repeat protein (DARPin) for HER2 imaging [PDF]
, 2015 Background: Human epidermal growth factor receptor-2 (HER2) expression predicts response to anti-HER2 therapy in breast and gastric cancer. HER2 status is assessed by tumour biopsy but this may not be representative of the larger tumour mass or other ...
Goldstein, RM
core
PABPC1 in Cancer: From a Translational Housekeeper to a Stress‐Responsive Regulatory Hub
Cancer Science, EarlyView.PABPC1 shifts from a translational housekeeper to a stress‐responsive oncogenic hub via phase separation, PTMs, and non‐coding RNA crosstalk, selectively driving oncogene translation and therapy resistance in cancer. ABSTRACT PABPC1, long recognized as a constitutive translational housekeeper, has emerged as a stress‐responsive translational ...
Cuiwei Zhang, Ye Zhu, Wenbo Long
wiley +1 more source
CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems
The FEBS Journal, EarlyView.Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén +11 more
wiley +1 more source
Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
, 2014 Drew R Oostra,1 Erin R Macrae21Division of Hematology, Oncology, and Transplant. University of Minnesota, Minneapolis, MN, USA; 2Division of Medical Oncology, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH,
Macrae ER, Oostra DR
core
A guide to transcriptional cyclin‐dependent kinases in cancer
The FEBS Journal, EarlyView.Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin +2 more
wiley +1 more source
Breast cancer therapy and cardiovascular risk: focus on trastuzumab
, 2015 Aamer Sandoo,1,2 George D Kitas,2 Amtul R Carmichael2 1School of Sport, Health and Exercise Sciences, Bangor University, Bangor, Wales, 2Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, UK Abstract: Breast cancer is the most common ...
Kitas GD, Carmichael AR, Sandoo A
core
Epigenetic control of cellular plasticity in breast cancer progression
The FEBS Journal, EarlyView.Cancer cells undergo cell state transitions, termed plasticity, driving cancer progression and dictating therapeutic response. We define breast cancer plasticity into four interconnected processes: (1) breast cancer stem cell fates, (2) epithelial‐to‐mesenchymal transition, (3) maintenance of luminal identity, and (4) acquisition of therapeutic ...
Ellie J. Massey +2 more
wiley +1 more source
, 2014 Masataka SawakiDepartment of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, JapanAbstract: Anti-HER2 agents, such as trastuzumab, lapatinib, trastuzumab emtansine (T-DM1), and pertuzumab, are standard agents in the treatment of breast cancer ...
Sawaki M
core